On January 17, Jinghua Pharmaceutical Group Co.Ltd(002349) rose again, and the share price closed at 16.09 yuan / share. So far, Jinghua Pharmaceutical Group Co.Ltd(002349) has closed three trading boards.
“mother” is expensive by “son”
In fact, this is not the first consecutive trading since Jinghua Pharmaceutical Group Co.Ltd(002349) 2022.
According to the data, from December 24, 2021 to January 5, 2022, Jinghua Pharmaceutical Group Co.Ltd(002349) shares closed at the limit price for eight consecutive trading days, with a cumulative increase of 114.62%. During this period, the company’s share price hit a new high in recent three years, up to 13.65 yuan / share.
However, the good times did not last long. After closing eight trading boards in a row, Jinghua Pharmaceutical Group Co.Ltd(002349) share prices plunged. As of the closing on January 7, the company’s share price closed at 11.22 yuan / share, down 17.8% in two trading days.
The stock price is like a roller coaster. How good is Jinghua Pharmaceutical Group Co.Ltd(002349) on the “covid-19 oral medicine” concept stock express?
According to the data, Jinghua Pharmaceutical Group Co.Ltd(002349) was listed in 2010 and its main business is the R & D, production and sales of traditional Chinese patent medicine preparations, chemical raw materials and intermediates, chemical pharmaceutical intermediates, traditional Chinese medicine and traditional Chinese medicine pieces, biopharmaceuticals, etc.
According to the trading public information of Shenzhen Stock Exchange, on December 27, 2021, December 30, 2021 and January 5, 2022, Jinghua Pharmaceutical Group Co.Ltd(002349) has reached 21.21%, 29.07% and 21.84% in total due to the deviation of price increase during the abnormal period. On January 7, the company was listed on the list because the deviation value of daily price decline reached 8.85%. The famous “Lhasa Legion” business department in the market appeared to buy and sell seats.
Jinghua Pharmaceutical Group Co.Ltd(002349) has been on the dragon and tiger list one after another, which has something to do with the speculation of hot money. On December 22, 2021, Pfizer “paxlovid” was approved by FDA and became the first covid-19 oral drug in the United States. Affected by Pfizer’s specific drugs, pharmaceutical intermediates have become a hot concept in the market for a time.
Jiangsu senxuan Pharmaceutical Co., Ltd., a holding subsidiary of Jinghua Pharmaceutical Group Co.Ltd(002349) , is an enterprise producing and selling ritonavir series pharmaceutical intermediates.
Tianyancha app shows that senxuan pharmaceutical’s main business is the R & D, production and sales of pharmaceutical intermediates and chemical intermediates. The company’s products are mainly used in drug synthesis, chemical reaction catalysts, chemical solvents, etc.
In order to ensure the development and growth of senxuan pharmaceutical API business, on October 27, 2021, Jinghua Pharmaceutical Group Co.Ltd(002349) sold 100% equity of its wholly-owned subsidiary Shanghai Sutong Biotechnology Co., Ltd. to senxuan pharmaceutical at the price of 7.737 million yuan.
Although senxuan medicine replied to investors from January 10 to 14 that the company neither produced the API of covid-19 oral drug vv116 nor conducted the production and marketing business of covid-19 pneumonia API, it could not stop the sharp rise of share price.
Since 2022, senxuan pharmaceutical’s share price has soared by 269.26%. From December 29 to 30, 2021, senxuan pharmaceutical’s share price has been limited for two consecutive trading days, becoming the first stock with continuous limit in the Beijing stock exchange. The company has also been on the dragon and tiger list for 13 times.
In the short term, the stock price soared, and senxuan medicine coincided with the arrival of massive lifting of the ban.
It is understood that senxuan medicine will launch 345 million shares on January 27, lifting the ban on the listing of restricted shares of the original shareholders, accounting for 80.96% of the total share capital. After the lifting of the ban, the circulation of the company will increase by about four times.
The lifting of the ban involves two shareholders, the parent company Jinghua Pharmaceutical Group Co.Ltd(002349) and the natural person Tong Zhenming, who are the first and second largest shareholders of the company. According to the latest stock price, the market value of Tong Zhenming’s lifting of the ban exceeds 1 billion yuan.
The sharp rise in the share price of its subsidiary senxuan medicine also drove the share price of Jinghua Pharmaceutical Group Co.Ltd(002349) . Jinghua Pharmaceutical Group Co.Ltd(002349) gained 11 trading boards, and the share price increased by 143.83%, truly realizing the “mother depends on son”.
shareholders’ high-level reduction
After the continuous rise of Jinghua Pharmaceutical Group Co.Ltd(002349) share price, shareholders and executives of the company chose to reduce their holdings and cash out at a high level.
On December 22, Nantong variety Investment Co., Ltd., which holds Jinghua Pharmaceutical Group Co.Ltd(002349) 9.77% of the shares, and min Shengda, the person acting in concert, planned to reduce the company’s shares by a total of no more than 16.714 million shares (i.e. no more than 2% of the company’s total shares) through centralized bidding.
Ten days later, Jinghua Pharmaceutical Group Co.Ltd(002349) received the share reduction plan from Zhou Yunzhong, the director and general manager of the company, and planned to reduce the total shares of the company by means of centralized competitive trading at the stock exchange, accounting for no more than 967000 shares, accounting for 0.12% of the total share capital of the company.
With regard to the sharp rise of Jinghua Pharmaceutical Group Co.Ltd(002349) share price, the reduction of shareholders’ holdings, the strengthening of the company’s main business and covid-19 oral medicine, this newspaper has sent an interview letter to the enterprise. As of the press time, it has not replied yet.
